MIXED RESULTS WITH PD DRUG IN ALZHEIMER'S PSYCHOSIS

MedPage Today - Oral pimavanserin (Nuplazid) demonstrated some efficacy in Alzheimer's disease psychosis, but only in the short term, according to results of a phase II trial. The selective 5-HT2A receptor inverse agonist and antagonist met it's primary efficacy endpoint of reducing psychosis score after 6 weeks of treatment versus placebo (-3.76 points versus -1.93 placebo, 95% CI -3.64 to -0.04,P=0.045), reported Clive Ballard, MD, of Exeter University in England, and colleagues. However, there was no significant treatment difference found between the groups after 12 weeks of treatment (-0.51, 95% CI -2.23 to 1.21, P=0.561), they wrote in the Lancet Neurology... >>>